

# **Pembrolizumab Solid Formulation**

Version **Revision Date:** SDS Number: Date of last issue: 30.09.2023 525367-00019 4.2 06.04.2024 Date of first issue: 23.02.2016

**SECTION 1: IDENTIFICATION** 

Pembrolizumab Solid Formulation Product name

Manufacturer or supplier's details

Company MSD

Building A - Level 1/26 Talavera Rd Address

Macquarie Park NSW, Australia 2113

Telephone 1 800 033 461

Emergency telephone number : Poisons Information Centre: Phone 13 11 26

E-mail address EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use Pharmaceutical Restrictions on use Not applicable

### **SECTION 2. HAZARDS IDENTIFICATION**

**GHS Classification** 

Reproductive toxicity : Category 1B

Specific target organ toxicity - : Category 1 (Immune system) repeated exposure (Oral)

**GHS** label elements

Hazard pictograms

Signal word Danger

Hazard statements H360D May damage the unborn child.

H372 Causes damage to organs (Immune system) through

prolonged or repeated exposure if swallowed.

Precautionary statements Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.



# **Pembrolizumab Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 525367-00019 4.2 06.04.2024 Date of first issue: 23.02.2016

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

#### Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

#### **SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Sucrose	57-50-1	>= 60 -<= 100
Pembrolizumab	1374853-91-4	>= 10 -< 30

#### **SECTION 4. FIRST AID MEASURES**

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

If in eyes, rinse well with water. In case of eye contact

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting. If swallowed

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms May damage the unborn child.

and effects, both acute and

delayed

Causes damage to organs through prolonged or repeated

exposure if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.



# **Pembrolizumab Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.2 06.04.2024 525367-00019 Date of first issue: 23.02.2016

Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

#### **SECTION 5. FIREFIGHTING MEASURES**

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment.

Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### **SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items



# **Pembrolizumab Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.2 06.04.2024 525367-00019 Date of first issue: 23.02.2016

employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### **SECTION 7. HANDLING AND STORAGE**

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust. Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

## **SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Sucrose	57-50-1	TWA	10 mg/m3	AU OEL
		TWA	10 mg/m3	ACGIH
Pembrolizumab	1374853-91-	TWA	450 μg/m3 (OEB	Internal



# **Pembrolizumab Solid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 4.2
 06.04.2024
 525367-00019
 Date of first issue: 23.02.2016

4 2)

**Engineering measures** : Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type Hand protection Particulates type

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending

on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the

end of workday.

Eye protection : Wear the following personal protective equipment:

Safety goggles

Skin and body protection : Select appropriate protective clothing based on chemical

resistance data and an assessment of the local exposure

potential.

Skin contact must be avoided by using impervious protective

clothing (gloves, aprons, boots, etc).

### **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : powder

Colour : white to off-white

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available



# **Pembrolizumab Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.2 06.04.2024 525367-00019 Date of first issue: 23.02.2016

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

#### **SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.



# **Pembrolizumab Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.2 06.04.2024 525367-00019 Date of first issue: 23.02.2016

Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.
Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

#### **SECTION 11. TOXICOLOGICAL INFORMATION**

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

## **Acute toxicity**

Not classified based on available information.

#### Components:

Sucrose:

Acute oral toxicity : LD50 (Rat): 29,700 mg/kg

#### Skin corrosion/irritation

Not classified based on available information.

### Serious eye damage/eye irritation

Not classified based on available information.

## Respiratory or skin sensitisation

### Skin sensitisation

Not classified based on available information.

### Respiratory sensitisation

Not classified based on available information.

#### **Chronic toxicity**

### Germ cell mutagenicity

Not classified based on available information.

### **Components:**

#### Sucrose:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative



# **Pembrolizumab Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.2 06.04.2024 525367-00019 Date of first issue: 23.02.2016

### Carcinogenicity

Not classified based on available information.

## Reproductive toxicity

May damage the unborn child.

### **Components:**

#### Pembrolizumab:

Reproductive toxicity - As-

May damage the unborn child., Based on data from similar

sessment materials

### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

Causes damage to organs (Immune system) through prolonged or repeated exposure if swallowed.

#### **Components:**

#### Pembrolizumab:

Target Organs : Immune system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

### Repeated dose toxicity

# **Components:**

#### Pembrolizumab:

Species : Monkey
NOAEL : 200 mg/kg
Application Route : Intravenous
Exposure time : 180 d

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 200 mg/kg
Application Route : Intravenous
Exposure time : 180 d

Remarks : No significant adverse effects were reported

### **Aspiration toxicity**

Not classified based on available information.

# Experience with human exposure

### **Components:**

#### Pembrolizumab:

Inhalation : Target Organs: Immune system



# **Pembrolizumab Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 525367-00019 4.2 06.04.2024 Date of first issue: 23.02.2016

> Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhoea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest., May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis

Remarks: Damage to fetus possible

#### **SECTION 12. ECOLOGICAL INFORMATION**

**Ecotoxicity** 

No data available

Persistence and degradability

No data available

Bioaccumulative potential

**Components:** 

Sucrose:

Partition coefficient: n-

octanol/water

: Pow: < 1

Mobility in soil

No data available

Other adverse effects

No data available

#### **SECTION 13. DISPOSAL CONSIDERATIONS**

**Disposal methods** 

Waste from residues Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Empty containers should be taken to an approved waste han-Contaminated packaging

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### **SECTION 14. TRANSPORT INFORMATION**

### **International Regulations**

**UNRTDG** 

**UN** number Not applicable Proper shipping name Not applicable Class Not applicable Subsidiary risk Not applicable Not applicable Packing group Labels Not applicable no

Environmentally hazardous

**IATA-DGR** 



# **Pembrolizumab Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.2 06.04.2024 525367-00019 Date of first issue: 23.02.2016

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen-

ger aircraft)

Not applicable

**IMDG-Code** 

**UN** number Not applicable Proper shipping name Not applicable Class Not applicable Subsidiary risk Not applicable Packing group Not applicable Not applicable Labels Not applicable EmS Code Not applicable Marine pollutant

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### **National Regulations**

**ADG** 

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Hazchem Code : Not applicable

Special precautions for user

Not applicable

#### **SECTION 15. REGULATORY INFORMATION**

Safety, health and environmental regulations/legislation specific for the substance or mixture

Therapeutic Goods (Poisons:

Standard) Instrument

No poison schedule number allocated (Please use the original publication to check for specific uses, specific conditions or

threshold limits that might apply for this chemical)

Prohibition/Licensing Requirements : There is no applicable prohibition,

authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regula-

tions.

The components of this product are reported in the following inventories:



# **Pembrolizumab Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.2 06.04.2024 525367-00019 Date of first issue: 23.02.2016

AICS : not determined

DSL : not determined

IECSC : not determined

# **SECTION 16: ANY OTHER RELEVANT INFORMATION**

**Further information** 

Revision Date : 06.04.2024

Sources of key data used to

compile the Safety Data eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

AU OEL : Australia. Workplace Exposure Standards for Airborne Con-

Internal technical data, data from raw material SDSs, OECD

taminants.

ACGIH / TWA : 8-hour, time-weighted average

AU OEL / TWA : Exposure standard - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Sub-



# **Pembrolizumab Solid Formulation**

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 4.2 06.04.2024 525367-00019 Date of first issue: 23.02.2016

stances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN